

Supplementary File

Table S1. Variation in the use of different fractionation schedules throughout the studied period

	Overall n = 3357 (%)	2018 n = 924 (%)	2019 n = 865 (%)	2020 n = 668 (%)	2021 n = 900 (%)	p
1	1301(39)	248 (27)	272 (31)	390 (58)	391 (44)	
2–4	1225(36)	438 (47)	375 (44)	132 (20)	280 (31)	< 0.001
≥ 5	831(25)	238 (26)	218 (25)	146 (22)	229 (25)	

Table S2. Univariate analysis investigating potential risk factors of 30-day mortality (30-DM)

		OR	CI 95%	p-value
Gender	Male	–	0.62–0.91	0.03
	Female	0.750		
Age (years)	> 65	–	0.76–1.11	0.39
	≤ 65	0.920		
Health Insurance	Public	–	0.63–0.98	0.03
	Private	0.78		
	Others	1.16		
ECOG	0-2	–	0.26–0.40	<0.01
	3-4	0.32		
Metastases other than bone	No	–	1.66–2.59	<0.01
	Yes	2.07		
Fractions	>5	–	0.71–1.10	0.39
	2-5	0.90		
	1	0.74		
Primary tumor	Cervix-Uterine	–		

	Prostate	0.69	0.36–1.34	0.25
	Breast	0.78	0.45–1.43	0.39
	Haematologic	1.07	0.58–2.07	0.82
	Colorectal	1.33	0.74–2.52	0.35
	Esophageal-gastric	1.89	0.98–3.73	0.04
	Renal	1.34	0.70–2.64	0.39
	Others	1.66	0.98–3.00	0.07
	Lung	2.47	1.46–4.46	< 0.01
Treatment site	Head & neck	–		
	Intra-Pelvic	0.66	0.38–1.17	0.14
	Bone	0.75	0.48–1.24	0.24
	Intra-abdominal	0.98	0.54–1.79	0.94
	Skin-soft tissues	0.86	0.50–1.53	0.60
	Intra-thoracic	1.61	0.97–2.68	0.07
	Brain	1.97	1.21–3.33	< 0.01